Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

International Working Group consensus response evaluation criteria in lymphoma (RECIL 2017)

Research output: Contribution to journalReviewResearchpeer-review

DOI

  1. L-Lysine increased the cytotoxicity effect of doxorubicin in MDA-MB-231 and MDA-MB-468 breast cancer cell lines

    Research output: Contribution to journalConference articleResearchpeer-review

  2. TSGA10 and H2AX competition over binding HIF-1 in breast cancer

    Research output: Contribution to journalConference abstract in journalResearchpeer-review

  3. Human endogenous retroviruses and their implication for immunotherapeutics of cancer

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. A small change makes a big difference in Hodgkin lymphoma

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Improvements in Imaging of Hodgkin Lymphoma: Positron Emission Tomography

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Predictive value of PET response combined with baseline metabolic tumor volume in peripheral T-cell lymphoma patients

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Treatment strategies, outcomes and prognostic factors in 291 patients with secondary CNS involvement by diffuse large B-cell lymphoma

    Research output: Contribution to journalJournal articleResearchpeer-review

  • A Younes
  • P Hilden
  • B Coiffier
  • A Hagenbeek
  • G Salles
  • W Wilson
  • J F Seymour
  • K Kelly
  • J Gribben
  • M Pfreunschuh
  • F Morschhauser
  • H Schoder
  • A D Zelenetz
  • J Rademaker
  • R Advani
  • N Valente
  • C Fortpied
  • T E Witzig
  • L H Sehn
  • A Engert
  • R I Fisher
  • P-L Zinzani
  • M Federico
  • M Hutchings
  • C Bollard
  • M Trneny
  • Y A Elsayed
  • K Tobinai
  • J S Abramson
  • N Fowler
  • A Goy
  • M Smith
  • S Ansell
  • J Kuruvilla
  • M Dreyling
  • C Thieblemont
  • R F Little
  • I Aurer
  • M H J Van Oers
  • K Takeshita
  • A Gopal
  • S Rule
  • S de Vos
  • I Kloos
  • M S Kaminski
  • M Meignan
  • L H Schwartz
  • J P Leonard
  • S J Schuster
  • V E Seshan
View graph of relations

In recent years, the number of approved and investigational agents that can be safely administered for the treatment of lymphoma patients for a prolonged period of time has substantially increased. Many of these novel agents are evaluated in early-phase clinical trials in patients with a wide range of malignancies, including solid tumors and lymphoma. Furthermore, with the advances in genome sequencing, new "basket" clinical trial designs have emerged that select patients based on the presence of specific genetic alterations across different types of solid tumors and lymphoma. The standard response criteria currently in use for lymphoma are the Lugano Criteria which are based on [18F]2-fluoro-2-deoxy-D-glucose positron emission tomography or bidimensional tumor measurements on computerized tomography scans. These differ from the RECIST criteria used in solid tumors, which use unidimensional measurements. The RECIL group hypothesized that single-dimension measurement could be used to assess response to therapy in lymphoma patients, producing results similar to the standard criteria. We tested this hypothesis by analyzing 47 828 imaging measurements from 2983 individual adult and pediatric lymphoma patients enrolled on 10 multicenter clinical trials and developed new lymphoma response criteria (RECIL 2017). We demonstrate that assessment of tumor burden in lymphoma clinical trials can use the sum of longest diameters of a maximum of three target lesions. Furthermore, we introduced a new provisional category of a minor response. We also clarified response assessment in patients receiving novel immune therapy and targeted agents that generate unique imaging situations.

Original languageEnglish
JournalAnnals of Oncology
Volume28
Issue number7
Pages (from-to)1436-1447
Number of pages12
ISSN0923-7534
DOIs
Publication statusPublished - 1 Jul 2017

    Research areas

  • Antineoplastic Agents, Consensus, Contrast Media, Disease Progression, Disease-Free Survival, Endpoint Determination, Fluorodeoxyglucose F18, Humans, Lymphoma, Non-Hodgkin, Neoplasm Staging, Positron-Emission Tomography, Predictive Value of Tests, Response Evaluation Criteria in Solid Tumors, Time Factors, Tomography, X-Ray Computed, Treatment Outcome, Tumor Burden, Consensus Development Conference, Journal Article, Practice Guideline, Review

ID: 52764973